Loading...
Loading...
Minverva Biosciences
NERV shares are trading higher by $6.30 at $9.84 in Thursday's session. The issue bolted to $15 in premarket trading after the announcement that MIN-101 monotherapy for depression meets primary and secondary endpoints before falling back to the $10 area.
Off the open, it rallied to $$10.60 before some profit takers came in. The ensuing decline took it down to $8.25, but now is attempting the $10 handle.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in